DYNE THERAPEUTICS INC (DYN) Stock News

USA - Nasdaq - NASDAQ:DYN - US26818M1080 - Common Stock

21.9 USD

+0.73 (+3.45%)

Last: 11/28/2025, 8:24:59 PM

21.9 USD

0 (0%)

After Hours: 11/28/2025, 8:24:59 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DYN Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: The Motley Fool - Mentions: BCRX ACAD ASND RY ...

Why Dyne Therapeutics Stock Was Crushing it This Week

12 days ago - By: Benzinga - Mentions: TERN SGML COCO IVVD ...

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday

24 days ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

24 days ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

a month ago - By: Stocktwits - Mentions: RNA NVS

News Image

Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis

4 months ago - By: The Motley Fool

Dyne Reports Wider Loss in Fiscal Q2

a month ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at Upcoming Investor Conferences

a month ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at Upcoming Investor Conferences

a month ago - By: Benzinga - Mentions: PRE GNTA RNA SMLR ...

12 Health Care Stocks Moving In Monday's Intraday Session

2 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

2 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

2 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

2 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Appoints Brian Posner to its Board of Directors

2 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

2 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

3 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at Upcoming Investor Conferences

3 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics to Present at Upcoming Investor Conferences

3 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

4 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: Dyne Therapeutics, Inc.

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN

4 months ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN